SCHEMBL5949509

SCHEMBL5949509

O[C@@H](Cc1ccccn1)c1ccc(Br)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 3/20 0.50
▸ PTPRA P18433 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.49
▸ GRIN2D O15399 1/20 0.47
▸ GRIN3B O60391 1/20 0.47
▸ GRIN1 Q05586 1/20 0.47
▸ GRIN2A Q12879 1/20 0.47
▸ GRIN2B Q13224 1/20 0.47
▸ GRIN2C Q14957 1/20 0.47
▸ GRIN3A Q8TCU5 1/20 0.47
▸ FDPS P14324 1/20 0.46
▸ KMT2A Q03164 1/20 0.44
▸ CHRM2 P08172 2/20 0.41
▸ CHRM1 P11229 2/20 0.41
▸ DRD1 P21728 2/20 0.41
▸ SLC6A2 P23975 2/20 0.41
▸ SLC6A4 P31645 2/20 0.41
▸ HRH1 P35367 2/20 0.41
▸ SLC6A3 Q01959 2/20 0.41
▸ KCNH2 Q12809 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5948990 1.00 IGF1R (0.50) IGF1RPTPRAKDM4EGRIN2DGRIN3B
SCHEMBL5949323 1.00 IGF1R (0.50) IGF1RPTPRAKDM4EGRIN2DGRIN3B
SCHEMBL9491676 0.86 KDM4E (0.63) PTPRAKDM4EGRIN2DGRIN3BGRIN1
SCHEMBL22728750 0.86 KDM4E (0.63) PTPRAKDM4EGRIN2DGRIN3BGRIN1
SCHEMBL5949434 0.83 GRIN2D (0.47) PTPRAKDM4EGRIN2DGRIN3BGRIN1
SCHEMBL11322072 0.80 GRIN2D (0.47) PTPRAGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL27543486 0.80 PTPRA (0.50) PTPRAKDM4EGRIN2DGRIN3BGRIN1
SCHEMBL25229735 0.80 PTPRA (0.46) PTPRAKDM4EGRIN2DGRIN3BGRIN1
SCHEMBL6559702 0.80 MAOA (0.52) PTPRAKDM4EGRIN2DGRIN3BGRIN1
SCHEMBL11084913 0.80 MEN1 (0.50) PTPRAKDM4EGRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211731-A1 New substituted pyridine or piperidine compounds LES LABORATORIES SERVIER (FR) 2006-09-21 — — US disclosed
US-20050004168-A1 New substituted pyridine or piperidine compounds METH-COHN OTTO (GB) 2005-01-06 — — US disclosed
EP-1050531-B1 Pyridine and piperidine derivatives for treating neurodegenerative diseases SERVIER LAB (FR) 2004-11-17 — — EP disclosed
US-6734196-B2 ANALGESICS; COGNITION ACTIVATORS LES LABORATOIRES SERVIER (FR) 2004-05-11 — — US disclosed
US-6638946-B2 1-(4-bromophenyl)-2-(1-methyl-2-piperidinyl)-1-ethanone, for example; treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Korsakoff's disease and frontal lobe and subcortical dementias LES LABORATOIRES SERVIER (FR) 2003-10-28 — — US disclosed
US-20030181484-A1 New substituted pyridine or piperidine compounds METH-COHN OTTO (GB) 2003-09-25 — — US disclosed
US-20030139408-A1 Substituted pyridine or piperidine compounds METH-COHN OTTO (GB) 2003-07-24 — — US disclosed
US-6511992-B2 For treating pain or memory deficiencies related to Alzheimer's disease and other neurodegenerative disorders associated with aging LES LABORATORIES SERVIER (FR) 2003-01-28 — — US disclosed
US-20020040036-A1 New substituted pyridine or piperidine compounds ADIR ET COMPAGNIE 2002-04-04 — — US disclosed
US-20020035123-A1 New substituted pyridine or piperidine compounds ADIR ET COMPAGNIE 2002-03-21 — — US disclosed
US-6323220-B1 COGNITION ACTIVATORS AND TREATMENT OF NERVOUS SYSTEM DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-27 — — US disclosed
EP-1050531-A1 Pyridine and piperidine derivatives for treating neurodegenerative diseases ADIR ET COMPAGNIE (FR) 2000-11-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181484-A1 New substituted pyridine or piperidine compounds CNR1, HRH4, OPRD1 IGF1R 3395/4885PTPRA 4068/4885KDM4E 1888/4885
US-20060211731-A1 New substituted pyridine or piperidine compounds HRH3, P2RY1, CHRM1 IGF1R 2211/4885PTPRA 3586/4885KDM4E 1816/4885
US-20030139408-A1 Substituted pyridine or piperidine compounds P2RY1, HRH3, CNR1 IGF1R 3320/4885PTPRA 3993/4885KDM4E 1656/4885
US-20050004168-A1 New substituted pyridine or piperidine compounds HRH3, HRH4, HRH1 IGF1R 2510/4885PTPRA 3885/4885KDM4E 2366/4885
US-20020035123-A1 New substituted pyridine or piperidine compounds OPRD1, CNR1, HRH4 IGF1R 3211/4885PTPRA 4002/4885KDM4E 1930/4885
US-20020040036-A1 New substituted pyridine or piperidine compounds CNR1, OPRD1, OPRK1 IGF1R 2791/4885PTPRA 3942/4885KDM4E 2121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback